

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-0155US1	Application No. 10/564,665
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Reiko Irie et al.	
		Filing Date September 21, 2006	Group Art Unit 1644
(37 CFR §1.98(b))			

U.S. Patent Documents						
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	1	WO 03/046162	06/05/2003	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	2	Hoon et al., "Molecular cloning of a human monoclonal antibody reactive to ganglioside G <sub>M3</sub> antigen on human cancers," <i>Cancer Res.</i> , 53:5244-5250 (1993)
	3	Irie et al., "Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma," <i>Cancer Immunol. Immunother.</i> , 53:110-117 (2004)
	4	Youd et al., "Synergistic roles of IgM and complement in antigen trapping and follicular localization," <i>Eur. J. Immunol.</i> , 32:2328-2337 (2002)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	